Less than three months after linking up with Takeda Pharmaceutical Co. Ltd., the UK's Evox Therapeutics Ltd. has bagged another big pharma partner and signed a multi-target RNA interference (RNAi) and antisense pact looking at potential treatments for neurological disorders with Eli Lilly & Co..
UK's Evox Gets Lilly Onboard For CNS Exosome Collaboration
Banks $20m Up Front
The US major will work with Evox Therapeutics on potential treatments of neurological disorders using the Oxford-based firm's DeliverEX platform.
More from Neurological
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.